New hope for a universal immunotherapy
Scientists led by the University of Pennsylvania have developed nanoparticles that could make a more universal form of cancer immunotherapy possible, cutting out the time and cost of patient-specific approaches. The work appears in Nature Nanotechnology.
What these nanoparticles do
Think of the particles as a quick pick-me-up for the immune system. They counter the gradual exhaustion of T cells that happens inside tumors and give those cells back the energy and signals they need to attack cancer.
T cell exhaustion is a major barrier for current immunotherapies. T cells are the white blood cells that spot and destroy cancer, but in solid tumors they often become weak and ineffective because of the hostile tumor environment.
How the particles work
The nanoparticles carry two different payloads at the same time:
- A drug that prevents the tumor from producing an enzyme that would otherwise suppress immune activity.
- An mRNA molecule that gives cells the instructions to make a protein which activates the immune system.
As Qiangqiang Shi, the first author on the study, explains, the particles both release the brake and refuel the T cells. The project was coordinated by Michael J. Mitchell.
Encouraging results in mice
In mouse tests the nanoparticles almost completely cleared colon tumors within about 30 days. Animals that recovered also became resistant to tumor recurrence. In mice carrying two tumors, injecting the particles into one tumor led to regression of the untreated tumor as well.
Why this matters
If these findings translate to humans, the approach could simplify immunotherapy by eliminating the need to design custom treatments for each patient. That could lower both the time and cost required to get effective immune-based therapies to more people.
Next steps include further studies to confirm safety and effectiveness beyond mice, and to work out how this technology might be adapted for different cancer types.
